Display options
Cite
Maurer MS, Mundayat R, Rapezzi C. Reply: Val122Ile mt-ATTR Has a Worse Survival Than wt-ATTR Cardiac Amyloidosis. J Am Coll Cardiol. 2017;69(6):758-759doi: 10.1016/j.jacc.2016.11.047.
Maurer, M. S., Mundayat, R., & Rapezzi, C. (2017). Reply: Val122Ile mt-ATTR Has a Worse Survival Than wt-ATTR Cardiac Amyloidosis. Journal of the American College of Cardiology, 69(6), 758-759. https://doi.org/10.1016/j.jacc.2016.11.047
Maurer, Mathew S, et al. "Reply: Val122Ile mt-ATTR Has a Worse Survival Than wt-ATTR Cardiac Amyloidosis." Journal of the American College of Cardiology vol. 69,6 (2017): 758-759. doi: https://doi.org/10.1016/j.jacc.2016.11.047
Maurer MS, Mundayat R, Rapezzi C. Reply: Val122Ile mt-ATTR Has a Worse Survival Than wt-ATTR Cardiac Amyloidosis. J Am Coll Cardiol. 2017 Feb 14;69(6):758-759. doi: 10.1016/j.jacc.2016.11.047. PMID: 28183521.
Copy Download .nbib Format: NLM
Share it on

J Am Coll Cardiol. 2017 Feb 14;69(6):758-759. doi: 10.1016/j.jacc.2016.11.047.

Reply: Val122Ile mt-ATTR Has a Worse Survival Than wt-ATTR Cardiac Amyloidosis.

Journal of the American College of Cardiology

Mathew S Maurer, Rajiv Mundayat, Claudio Rapezzi

PMID: 28183521 DOI: 10.1016/j.jacc.2016.11.047

[No abstract available.]

MeSH terms

Publication Types